JNJ
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals
Johnson & Johnson
$272.32
-4.00 (-1.45%)
JNJ News30 articles
S&P 500 Bounces Back as Yields Slip, Healthcare Surges
The S&P 500 reversed early losses by Thursday afternoon, buoyed by falling Treasury yields and a 2.6% surge in healthcare, while tech remained weak.
S&P 500 Flat as Breadth Diverges from Bank, Chip Weakness
U.S. stocks finished slightly lower Tuesday, though most S&P 500 components gained. Banking and healthcare losses offset positive breadth.
Dow Wipes Out 395-Point Gain as Earnings Pop Fades
The Dow surrendered a 395-point opening rally by midday Tuesday, with Goldman Sachs and UnitedHealth giving back early gains while Johnson & Johnson plunged 6.85%.
Dow Hits Record High as Chip Slump Splits Wall Street
The Dow climbed to a record high Tuesday as strong bank earnings offset a global chip selloff, while the Nasdaq slipped and the S&P 500 stayed flat.
S&P 500 Trims Losses as Late Treasury Auction Relief Lifts Markets
The S&P 500 pared a 0.71% intraday slide to close 0.22% lower, aided by strong 10-year Treasury demand. Small caps fell 1.31% as defensive rotation persisted.
J&J Reveals Rybrevant Survival Data Presentation, But Numbers Stay Under Wraps
Johnson & Johnson confirmed final overall survival data from its Phase 3 PAPILLON trial will be presented at a presidential symposium, but the results remain under embargo.
Pfizer Stock Hits 52-Week High at 10x Forward Earnings
Pfizer shares climbed 1.7% to $29.04, hitting a 52-week high, as the stock trades at 10x projected 2026 earnings, with a 5.9% dividend yield.
XLV Retreats from Record as Mid-Sized Health Care Names Lag
XLV hit a record $169.71 before closing lower, lagging the S&P 500 by 0.74 points. Weakness among smaller health care holdings offset gains in top components.
Bristol Myers Unveils $2.3B Houston Facility for Flexible Drug Production
Bristol Myers Squibb (BMY) will build a $2.3 billion drug-manufacturing campus in Houston, supporting small molecules, biologics, and antibody-drug conjugates, with nearly 500 skilled jobs.
J&J Shares Hold Ground Despite 5.5% EPS Guidance Cut
Johnson & Johnson (NYSE:JNJ) closed at $259.24 on Friday, up 0.9%, despite a 5.5% cut to its 2026 adjusted EPS guidance. Investors appear to view the dilution as pipeline investment.
Dow Drops 370 Points as Five Stocks Drive Most of the Decline
The Dow Jones Industrial Average fell 370 points, with five stocks accounting for 59% of the decline. Broader markets showed resilience, suggesting sector rotation.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Dow Gains 300 Points, But Microsoft Alone Drives the Rally
The Dow Jones rose 304 points on July 30, 2026, but Microsoft alone accounted for 356 points of the gain, masking weakness in other sectors.
Gossamer Bio Stock Jumps on FDA Filing Update, but Cash and Dilution Risks Remain
Gossamer Bio shares surged after an FDA filing update, but cash concerns and potential dilution continue to weigh on the stock.
Market Update: TBC Bank's High Yield, J&J Endorsed, and Key Movers
TBC Bank delivers a 5.4% yield, Jim Cramer backs Johnson & Johnson, and Micron leads UK S&P 500 buys amid AI demand.
Dow Flat as Software Slide Offsets Goldman's Gains
The Dow ended nearly flat on Wednesday as a decline in software stocks, led by Microsoft and Salesforce, countered a boost from Goldman Sachs.
Dow Rises 142 Points; Two Stocks Drive Nearly 70% of Gain
The Dow Jones Industrial Average climbed 142 points by midday Wednesday, with Caterpillar and Goldman Sachs accounting for nearly 70% of the gain.
Chip Sector Slide Masks Broad Earnings Strength in S&P 500
S&P 500 fell 0.51% to 7,533.77 as chip stocks dropped 4.3%, offsetting earnings beats from 75% of components. UnitedHealth and Morgan Stanley reported strong results.
Eli Lilly Shares Gain on Atai Deal with $1 Billion Milestone Potential
Eli Lilly shares edged up 1.08% on a $3.8B deal with Atai Life Sciences, which could unlock up to $1 billion in milestone payments for psychedelic depression drugs.
Abbott Leads Healthcare Surge as Insurers Show Mixed Results
Abbott Laboratories surged 10.9% despite a modest earnings beat, while UnitedHealth rose 2.6% on a larger beat. The healthcare sector ETF XLV gained 2.2%.
J&J's Q2 Growth Largely Relies on Two Key Drugs
Johnson & Johnson's Q2 sales growth was almost entirely driven by Tremfya and Darzalex, raising concerns about portfolio depth. MedTech missed estimates.
NextCure Shares Skyrocket on Merger Deal, But Investors Eye Cash Payout
NextCure shares jumped 176.6% on merger news with Avere Therapeutics, but existing holders will own just 1.21% of the combined firm, focusing on a possible cash payout.
US Futures Mixed as Treasury Yields Climb, Earnings Season Intensifies
US stock futures trade mixed as 10-year Treasury yields rise, pressuring rate-sensitive sectors. Earnings from JPMorgan, Goldman Sachs, and Netflix are in focus.
Pfizer's 7% Dividend Yield Attracts Income Seekers Amid Market Turmoil
Pfizer (PFE) added 1.28% in post-market trading Monday, outperforming the broader market as investors rotated into defensive stocks amid geopolitical tensions and a tech selloff.
Bank Earnings, TSMC, and Netflix to Test Market's Profit Outlook
This week's earnings from major banks, TSMC, and Netflix will test whether profit growth can broaden beyond tech and energy without exposing credit weakness.
Healthcare Earnings Test: J&J, UnitedHealth, Abbott in Focus After Sector's 9% Drop
Major healthcare stocks report this week as the sector's 9% earnings decline goes under the microscope. J&J, UnitedHealth, and Abbott are key to determining if the drop is real or just a one-off.
Pfizer Stock Rebounds After HSBC Downgrade, Dividend Yield Nears 7%
Pfizer shares recover some losses after HSBC downgrades the stock to Hold, slashing its price target by $4 to $28, as the dividend yield remains near 7%.
Pfizer's 7% Yield Beckons as Stock Lingers Near $24
Pfizer (PFE) trades near $24 with a 7.1% yield after a flat week. The company's Q1 dividends rivaled R&D spending, underscoring a focus on shareholder returns.
Lilly's GLP-1 Dominance Drives Near-Record Close, But Healthcare Rally Broadens
Eli Lilly closed near a record as XLV gained 2.65%, but other healthcare stocks like Johnson & Johnson and AbbVie drove more of the ETF's rise. Attention now turns to Lilly's $50 Medicare obesity drug offer and generic tirzepatide filings.
Pfizer's 7% Yield Attracts Income Seekers as Pharma Sector Stalls
Pfizer shares edged up 1.84% to $24.32, offering a 7.07% yield, but the stock has declined 14.12% over the past three months amid a sluggish pharmaceutical sector.